PQ Bypass, Inc. announces the appointment of medical device executive Stanton J. Rowe to its Board of Directors. As the medical technology company continues to achieve clinical milestones in its development of treatments for long blockages in leg arteries from PAD, expansion of the Board is important to meet the needs for future market expansion[…]

An implantable device that narrows the coronary sinus appears to be a good option for patients with refractory angina who are not candidates for further revascularization, real-world results from a single-center study suggest. The Reducer (Neovasc) is a stainless-steel, balloon-expandable, hourglass-shaped device that is implanted percutaneously to narrow the coronary sinus. Its use “ultimately leads[…]

Central venous occlusion is a significant, largely underestimated, and costly problem. An estimated 2 million people worldwide are currently either receiving treatment with dialysis or a kidney transplant, many of whom rely on central venous catheters (CVCs) to receive this lifesaving treatment. Despite being widely utilized, 40% of hemodialysis patients with CVCs develop a central[…]

Abbott Structural Heart announced the approval of the SUMMIT Pivotal trial of the Tendyne valve by the FDA. “Tendyne is a key part of our plan to provide patients and physicians a complete portfolio of repair and replacement solutions for treating the entire spectrum of mitral and tricuspid valve disease. Tendyne is already in clinical[…]

“In the U.S., there are approximately three million patients1 who may benefit from this therapy but are currently not being treated. This therapy may prove to be invaluable to these undertreated patients,” continued Sorajja. Dr. Paul Sorajja is the principal investigator of the study and performed the procedure along with Dr. Mario Gössl and Dr.[…]